Related Experiment Video
Updated: May 20, 2026
Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Effects of (5Z)-7-oxozeaenol on MDA-MB-231 breast cancer cells
Ulyana Muñoz Acuña1, Jennifer Wittwer, Sloan Ayers
1Division of Pharmacy Practice and Administration, College of Phamacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210-1291, USA.
Aim:
(5Z)-7-Oxozeaenol was studied to reveal the path through which it exerts its effects on triple-negative MDA-MB-231 breast cancer cells.
Materials And Methods:
The apoptotic effect of (5Z)-7-oxozeaenol on MDA-MB-231 cancer cells was analyzed by cell flow cytometry. The effects of (5Z)-7-oxozeaenol on the expression of the nuclear factor kappa B (NF-κB) p65, p50, IκB kinase (IKKα), IKKβ and caspase-7 were analyzed by western blot. The expression of intracellular reactive oxygen species (ROS) and effects on cell adhesion were also assessed. Cell viability was determined using the 3[4,5-dimethylthiazol-2-yl-]2,5-diphenyl tetrazolium bromide (MTT) assay.
Results:
(5Z)-7-Oxozeaenol down-regulated NF-κB in a dose-dependent manner. Intracellular levels of ROS increased in a dose-dependent manner when treated with (5Z)-7-oxozeaenol and potentiated in the presence of H(2)O(2), when compared to paclitaxel which was used as positive control. Treatment with (5Z)-7-oxozeaenol resulted in G1-phase arrest of treated cells and inhibition of cell proliferation. Cell adhesion was notably affected in treated cells. (5Z)-7-Oxozeaenol also significantly enhanced apoptosis of treated cells, through the activation of caspase-7.
Conclusion:
Our findings suggest that (5Z)-7-oxozeaenol is a potent up-stream inhibitor of the NF-κB pathway, enhances the sensitivity of treated cells to apoptosis induced by ROS, and affects cell adhesion of MDA-MB-231 breast cancer cells. Thus, (5Z)-7-oxozeaenol is a potential new lead for breast cancer drug development since it might, in combination therapy, enhance the efficacy of current treatments and reduce resistance to chemotherapy of triple negative breast cancer.
Insights
(5Z)-7-Oxozeaenol effectively inhibits triple-negative breast cancer cells by down-regulating NF-κB and promoting apoptosis. This natural compound shows promise in enhancing chemotherapy efficacy and overcoming drug resistance in breast cancer treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options.
- (5Z)-7-Oxozeaenol is a compound with potential anti-cancer properties.
Purpose of the Study:
- To investigate the anti-cancer mechanisms of (5Z)-7-Oxozeaenol on MDA-MB-231 triple-negative breast cancer cells.
- To elucidate the pathway through which (5Z)-7-Oxozeaenol exerts its effects.
Main Methods:
- Cell viability assays (MTT).
- Flow cytometry for apoptosis analysis.
- Western blotting for protein expression (NF-κB, IKK, caspase-7).
- Assessment of reactive oxygen species (ROS) and cell adhesion.
Main Results:
- (5Z)-7-Oxozeaenol dose-dependently down-regulated NF-κB signaling.
- Increased intracellular ROS levels and induced G1-phase cell cycle arrest.
- Enhanced apoptosis via caspase-7 activation and affected cell adhesion.
Conclusions:
- (5Z)-7-Oxozeaenol acts as an upstream inhibitor of the NF-κB pathway.
- It sensitizes cancer cells to ROS-induced apoptosis and impacts cell adhesion.
- (5Z)-7-Oxozeaenol is a potential lead compound for TNBC drug development, possibly in combination therapy.
